Table 3 Association between neutrophil–lymphocyte ratio and platelet–lymphocyte ratio, and mortality in 1435 Asian breast cancer patients

From: Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer

 

Total

Quintile 1

Quintile 2

Quintile 3

Quintile 4

Quintile 5

P trend a

Neutrophil–lymphocyte ratio, median

2.20

1.17

1.70

2.26

3.14

5.64

 

No. of patients

1435

226

379

305

331

194

 

No. of deaths

599

75

135

113

158

118

 

5-Year relative survival (95% CI)b

 

76.4 (69.6–82.1)

79.4 (74.4–83.7)

72.1 (66.3–77.3)

65.6 (59.8–70.8)

51.1 (43.3–58.5)

 

Crude hazard ratio (95% CI)

 

1.00

1.06 (0.80–1.41)

1.17 (0.87–1.56)

1.59 (1.21–2.10)c

2.56 (1.91–3.42)c

<0.001c

Adjusted hazard ratio (95% CI)d

 

1.00

1.03 (0.77–1.39)

1.04 (0.77–1.41)

1.27 (0.95–1.70)

1.50 (10.8–1.63)c

0.004c

Platelet–lymphocyte ratio, median

144.2

83.9

114.8

144.2

182.9

286.0

 

No. of patients

1435

287

287

287

287

287

 

No. of deaths

599

112

98

101

127

161

 

5-Year relative survival (95% CI)b

 

77.0 (70.9–82.2)

75.3 (69.4–80.5)

76.3 (70.4–81.4)

70.0 (64.0–75.4)

53.2 (46.9–59.2)

 

Crude hazard ratio (95% CI)

 

1.00

0.87 (0.67–1.15)

0.89 (0.68–1.16)

1.21 (0.94–1.55)

1.82 (1.43–2.31)c

0.001c

Adjusted hazard ratio (95% CI)e

 

1.00

0.82 (0.62–1.09)

0.87 (0.65–1.17)

0.92 (0.69–1.22)

1.07 (0.81–1.41)

0.376

  1. Abbreviation: CI=confidence interval.
  2. aP for trend is computed by entering the quintiles as a continuous term (score variable: 0, 1, 2, 3, 4) in the Cox model.
  3. bDerived using the Ederer II method; ratio of observed survival in women with breast cancer to the survival that would have been expected for the women of the general population, which is matched for age. Expected survival was derived from the Malaysian life table.
  4. cStatistically significant.
  5. dDerived using Cox regression adjusted for age at diagnosis, ethnicity, tumour size, number of positive axillary lymph nodes, distant metastasis, oestrogen/progesterone receptor status, HER2 status, tumour grade, lymphovascular invasion, type of surgery, radiotherapy, neoadjuvant chemotherapy, adjuvant chemotherapy regime, hormone therapy and platelet–lymphocyte ratio.
  6. eSimilar as model 3, but now adjusted for neutrophil–lymphocyte ratio.
Back to article page